Full Press Release Details
Lafayette, IN, August 1, 2005 Bioanalytical Systems, Inc.
(Nasdaq:BASI) announces that Edward M. Chait, Ph.D. is joining the company as
Executive Vice President and Chief Scientific Officer. Dr. Chait s last
assignment was CEO of Spectral Genomics, Inc., a biotechnology company in
Houston, Texas. Following a distinguished scientific career and positions of
increasing responsibility in marketing and business development at DuPont in
instrument and life science products (1968-1991), Dr. Chait held executive
positions in several life science companies and has served as an advisor to the
Purdue Cancer Center since 2002.
Peter Kissinger, Chairman and
CEO of BASi commented, I am delighted to bring Ed Chait back to West
Lafayette where he received his Ph.D. in analytical chemistry from Purdue
University. His particular background in discovery life sciences and instruments
is of great value for us, and his reputation and relationships in our industry
are a definite asset as we take BASi to the next level. Kissinger went on
to say, This is a position I ve wanted to fill for several years, and
in Ed we have found exactly the right person to take on critical major
responsibilities as we accelerate our growth.
his compensation package, the Company agreed to grant Dr. Chait incentive
options to purchase 25,000 common shares under its 1997 Employee Incentive Stock
Option Plan and non-qualified options to purchase an additional 25,000 of its
common shares outside the Option Plan, all at the per-share market price at the
close of business on the last trading day prior to the date Dr. Chait commences
employment with the Company. The option grants are contingent upon Dr. Chait
commencing employment with the Company.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical
development company providing contract research services and monitoring
instruments to the world s leading drug development companies and medical
research organizations. The company focuses on developing innovative services
and products that increase efficiency and reduce the cost of taking a new drug
http://www.bioanalytical.com for more about BASi.
Corporate Communications Director
BASi The Right-Size CRO
Ph 765.497.8458 Fax 765.497.1102
Preclinical, Clinical, Bioanalytical, Biomarkers and Pharmaceutical Analysis Contract
Services for thePharmaceutical Industry
Currently the same time as Chicago.